ENTRY       D10396                      Drug
NAME        Nintedanib esylate (USAN);
            Nintedanib ethanesulfonate (JAN);
            Ofev (TN)
PRODUCT     OFEV (Boehringer Ingelheim Pharmaceuticals)
FORMULA     C31H33N5O4. C2H6O3S
EXACT_MASS  649.257
MOL_WEIGHT  649.7571
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
            Metabolizing enzyme substrate
             DG02924  UGT substrate
            Transporter substrate
             DG01665  ABCB1 substrate
REMARK      Therapeutic category: 3999
            ATC code: L01EX09
            Chemical structure group: DG01374
            Product (DG01374): D10396<JP/US>
EFFICACY    Antifibrosis, Tyrosine kinase inhibitor
  DISEASE   Idiopathic pulmonary fibrosis [DS:H01299]
TARGET      VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            VEGFR3 (FLT4) [HSA:2324] [KO:K05097]
            PDGFR [HSA:5156 5159] [KO:K04363 K05089]
            FGFR1 (CD331) [HSA:2260] [KO:K04362]
            FGFR2 (CD332) [HSA:2263] [KO:K05093]
            FGFR3 (CD333) [HSA:2261] [KO:K05094]
  PATHWAY   hsa04010(2260+2261+2263+2321+2324+3791+5156+5159)  MAPK signaling pathway
            hsa04370(3791)  VEGF signaling pathway
            hsa05200(2260+2261+2263+2324+5156+5159)  Pathways in cancer
METABOLISM  Enzyme: UGT [KO:K00699]
            Transporter: ABCB1 [HSA:5243]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EX Other protein kinase inhibitors
                 L01EX09 Nintedanib
                  D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Respiratory Tract/Pulmonary Agents
              Pulmonary Fibrosis Agents
               Nintedanib
                D10396  Nintedanib esylate (USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D10396  Nintedanib esylate (USAN); Nintedanib ethanesulfonate (JAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01374  Nintedanib
                D10396  Nintedanib esylate
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG01374  Nintedanib
                D10396  Nintedanib esylate
             Transporter substrate
              DG01665  ABCB1 substrate
               DG01374  Nintedanib
                D10396  Nintedanib esylate
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               PDGFR family
                PDGFR
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
               FGFR family
                FGFR1 (CD331)
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
                FGFR2 (CD332)
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
                FGFR3 (CD333)
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
               VEGFR family
                VEGFR1 (FLT1)
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
                VEGFR2 (KDR)
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
                VEGFR3 (FLT4)
                 D10396  Nintedanib esylate (USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10396
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10396
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10396
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10396
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10396
             Drug transporters
              D10396
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01374  Nintedanib
             Metabolizing enzyme substrate
              DG02924  UGT substrate
               DG01374  Nintedanib
             Transporter substrate
              DG01665  ABCB1 substrate
               DG01374  Nintedanib
DBLINKS     CAS: 656247-18-6
            PubChem: 172232489
            ChEBI: 85170
ATOM        46
            1   S4a S    30.0803  -11.0132
            2   O1d O    30.0803   -9.6159
            3   O1d O    30.0803  -12.4804
            4   C1b C    28.6830  -11.0132
            5   O1d O    31.4776  -11.0132
            6   C1a C    27.9843   -9.8031
            7   C5a C    19.1800  -10.4300
            8   N1c N    17.9900   -9.7300
            9   C8y C    16.8000  -10.4300
            10  C8x C    15.5400   -9.7300
            11  C8y C    14.3500  -10.4300
            12  C8x C    14.3500  -11.8300
            13  C8x C    15.5400  -12.5300
            14  C8x C    16.8000  -11.8300
            15  N1b N    13.1600   -9.8000
            16  O5a O    19.1800  -11.8300
            17  N1y N    21.4200  -10.2200
            18  C1x C    21.4200  -11.6200
            19  C1x C    22.6100  -12.3200
            20  N1y N    23.8000  -11.6200
            21  C1x C    23.8000  -10.2200
            22  C1x C    22.6100   -9.5200
            23  C1a C    25.0600  -12.3200
            24  C1b C    20.1600   -9.5900
            25  C1a C    17.9900   -8.4000
            26  C2c C    12.0400  -10.5700
            27  C2y C    10.7800   -9.9400
            28  C8y C    12.0400  -11.9700
            29  C8x C    10.8500  -12.6700
            30  C8x C    10.8500  -14.0700
            31  C8x C    12.0400  -14.7700
            32  C8x C    13.3000  -14.0700
            33  C8x C    13.3000  -12.6700
            34  C5x C    10.5700   -8.5400
            35  N1x N     9.1700   -8.2600
            36  C8y C     8.4700   -9.5200
            37  C8y C     9.4500  -10.5700
            38  O5x O    11.5500   -7.5600
            39  C8x C     7.1400   -9.8700
            40  C8y C     6.7200  -11.2000
            41  C8x C     7.7000  -12.2500
            42  C8x C     9.1000  -11.9000
            43  O7a O     4.3400  -11.2000
            44  C7a C     5.5300  -11.9000
            45  O6a O     5.5300  -13.3000
            46  C1a C     3.1500  -11.9000
BOND        49
            1     1   2 2
            2     1   3 2
            3     1   4 1
            4     1   5 1
            5     4   6 1
            6     9  10 2
            7    10  11 1
            8    11  12 2
            9    12  13 1
            10   13  14 2
            11   14   9 1
            12   11  15 1
            13    7  16 2
            14    7   8 1
            15    8   9 1
            16   17  18 1
            17   18  19 1
            18   19  20 1
            19   20  21 1
            20   21  22 1
            21   22  17 1
            22   20  23 1
            23   17  24 1
            24    7  24 1
            25    8  25 1
            26   15  26 1
            27   26  27 2
            28   26  28 1
            29   28  29 2
            30   29  30 1
            31   30  31 2
            32   31  32 1
            33   32  33 2
            34   28  33 1
            35   27  34 1
            36   34  35 1
            37   35  36 1
            38   36  37 1
            39   27  37 1
            40   34  38 2
            41   36  39 2
            42   39  40 1
            43   40  41 2
            44   41  42 1
            45   37  42 2
            46   43  44 1
            47   44  40 1
            48   44  45 2
            49   43  46 1
///
